

# Content

<b>Abstract</b> .....	<b>1</b>
<b>Zusammenfassung</b> .....	<b>2</b>
<b>1 Introduction</b> .....	<b>4</b>
1.1 Glycosylation of therapeutic proteins .....	4
1.1.1 Mammalian N-Glycosylation .....	5
1.1.2 Eukaryotic expression platforms .....	7
1.2 Functional glycomics .....	8
1.3 Development of a production cell line .....	10
1.3.1 Glutamine synthetase as selection marker .....	13
1.3.2 Genome editing .....	15
1.4 CRISPR/Cas technology.....	18
1.4.1 History of CRISPR/Cas.....	18
1.4.2 CRISPR/Cas as immune defense mechanism.....	19
1.4.3 Application of CRISPR/Cas9 technology .....	22
1.5 Recombinase mediated cassette exchange.....	24
1.6 Aim of the project.....	28
<b>2 Material and Methods</b> .....	<b>30</b>
2.1 Chemicals.....	30
2.2 Cloning procedure .....	30
2.2.1 Polymerase chain reaction (PCR).....	30
2.2.2 Restriction .....	30
2.2.3 Agarose gel electrophoresis .....	30
2.2.4 Gel extraction and DNA quantification .....	31
2.2.5 Ligation.....	31
2.2.6 Cloning of gRNAs by DNA assembly .....	31
2.2.7 Transformation in E. coli .....	31
2.2.8 Plasmid extraction and sequencing .....	32
2.2.9 Linearization of plasmid DNA and purification of linearized DNA .....	32

2.3	Generation and cultivation of GEX® cell lines .....	33
2.3.1	Media and supplements for cell culture .....	33
2.3.2	Cultivation of GEX® cells .....	33
2.3.3	Small scale cultivation .....	34
2.3.4	Transfection .....	34
2.3.5	Single cell cloning .....	35
2.3.6	Cryoconservation and thawing of cells .....	35
2.4	Analysis of cells.....	36
2.4.1	RNA isolation and cDNA synthesis .....	36
2.4.2	Real-time quantitative PCR .....	36
2.4.3	Extraction of genomic DNA .....	36
2.4.4	Enzyme mismatch cleavage.....	37
2.4.5	In vitro Cas9 Assay .....	38
2.4.5.1	In vitro transcription of gRNAs .....	39
2.4.5.2	Cas9 cleavage with gRNA .....	39
2.4.6	TOPO-TA Cloning and sequencing .....	39
2.4.7	Deep Amplicon Sequencing .....	39
2.4.8	Targeted Locus Amplification .....	40
2.4.9	Extraction of cellular proteins and SDS-PAGE .....	41
2.4.10	Western Blot .....	41
2.4.11	Fluorescence activated cell sorting (FACS).....	42
2.4.12	Characterizing cell surface glycosylation .....	42
2.4.12.1	Lectin-based flow cytometry .....	42
2.4.12.2	Profiling of cell surface glycosylation .....	43
2.5	Analysis of glycoproteins and antibodies .....	43
2.5.1	FVII-Titer-ELISA.....	43
2.5.2	Determination of IgG-Titer .....	44
2.5.2.1	Determination of specific production rate .....	44
2.5.2.2	Batch cultivation for determination of maximum titer .....	44
2.5.3	Purification of glycoproteins .....	45
2.5.4	N-Glycan profiling.....	45
2.6	Software and databases.....	45

<b>3</b>	<b>Results</b>	<b>46</b>
3.1	Improving glycosylation of recombinant proteins	46
3.1.1	Generation of a GalNAc-deficient cell line	47
3.1.1.1	Genomic Analysis	47
3.1.1.2	Verification of mutations by Deep Amplicon Sequencing	53
3.1.1.3	Analysis of GalNAc-free FVII	56
3.1.2	Overexpression of sialyltransferase	59
3.1.2.1	Quantification of ST6 expression	59
3.1.2.2	Analysis of highly-sialylated FVII	62
3.1.3	Ambr cultivation	64
3.2	Optimizing timeline for clone development	67
3.2.1	Generation of GS-deficient cell lines	67
3.2.1.1	Western blot analysis	68
3.2.1.2	Genomic analysis	69
3.2.1.3	Verification of mutations by Deep Amplicon Sequencing	70
3.2.1.4	Glutamine dependency screening	71
3.2.2	Establishment of GS selection system	72
3.2.2.1	Generation of CM-producing clones	73
3.2.2.2	Comparison of the DHFR/MTX system with the GS/MSX system	74
3.2.2.3	Media screening	77
3.3	Increasing productivity and stability	81
3.3.1	Selection of loci for targeted integration	82
3.3.2	Plasmid construction	84
3.3.3	Generation of master cell lines	86
3.3.3.1	Strategy 1: Integration without antibiotic selection	87
3.3.3.2	Strategy 2: Random integration (w/ PuroR)	88
3.3.3.2.1	Strategy 2.A: Random integration in H9D8-GALNT(-) (w/ $\Delta$ NeoR)	89
3.3.3.2.2	Strategy 2.B: Random integration in H9D8-GALNT(-)-GS(-) (w/ $\Delta$ gs)	90
3.3.3.3	Strategy 3: Targeted integration (w/ PuroR)	91
3.3.3.3.1	Strategy 3.A: Targeted integration at hbg1 with exogenous promoter	91
3.3.3.3.2	Strategy 3.B: Targeted Integration at hdac9 with exogenous promoter	92
3.3.3.3.3	Strategy 3.C: Targeted Integration at hbg1 without promoter	92

3.3.3.4	Genomic Analysis .....	93
3.3.3.5	Analysis for stable eGFP expression .....	94
3.3.3.6	Comparison of clones generated by different strategies .....	95
3.3.3.7	Activin A-induced eGFP expression.....	96
3.3.4	Cre-mediated cassette exchange.....	98
3.3.4.1	Confirmation of functionality and specificity of the RMCE system .....	99
3.3.4.2	Analysis of Cre-treated pools.....	99
3.3.4.3	Resulting mCherry(Cre)-clones.....	101
3.3.4.3.1	Identification of strategy 1-derived mCherry(Cre)-clones.....	101
3.3.4.3.2	Identification of strategy 2.A-derived mCherry(Cre)-clones .....	102
3.3.4.3.3	Activin A-induced mCherry expression.....	103
3.3.4.3.4	Analysis for stable mCherry expression in mCherry(Cre)-P10020-A10 ..	103
3.3.4.3.5	Genomic Analysis .....	104
3.3.4.4	Resulting ST6(Cre)-clones.....	106
3.3.4.4.1	Identification of strategy 1-derived ST6(Cre)-clones.....	106
3.3.4.4.2	Identification of strategy 2.A-derived ST6(Cre)-clones .....	107
3.3.4.4.3	Comparison of the generated ST6(Cre)-clones .....	108
3.3.4.4.4	Analysis for stable ST6 expression in mCherry(Cre)-P10020-F12.....	109
3.3.4.4.5	Genomic analysis.....	109
3.3.5	Verification of integration sites by TLA technology .....	111
<b>4</b>	<b>Discussion .....</b>	<b>115</b>
4.1	CRISPR/Cas9n enables efficient gene editing.....	117
4.1.1	CRISPR/Cas9n allows multiplex knockouts of GalNAc-transferases .....	117
4.1.2	CRISPR/Cas9n allows the generation of a GS(-) cell line in a few month.....	120
4.1.3	Insertions sequences are derived from Cas9n-induced 5' overhangs.....	121
4.1.4	CRISPR/Cas9n mediates the efficient integration at targeted loci without altering surrounding regions .....	122
4.2	Glycoengineering improves glycan profile of rFVII.....	124
4.2.1	Knockout of b4galnt3 and b4galnt4 eliminates GalNAc structures.....	125
4.2.2	ST6 overexpression in a GalNAc-deficient clone generates a glycosylation pattern comparable to the plasma-derived FVII.....	126
4.2.3	Glycoengineering improves productivity of the FVII-production clone.....	127

4.3	Implementation of the GS selection system could improve the production of antibodies and glycoproteins.....	129
4.3.1	Generation of a GS-deficient cell line allows the selection in absence of toxic agents.....	130
4.3.2	Implementation of the GS-system achieves high specific productivity without amplification.....	130
4.3.3	Absence of glutamine can reduce glycolysis and prevents accumulation of toxic ammonia.....	132
4.3.4	Supplemented GTM FLEX shows no improvements towards the basic medium.....	135
4.4	Recombinase mediated cassette exchange enables reproducible generation of production clones.....	137
4.4.1	Targeting integration at hbg1 allows stable expression of various transgenes in GEX® cells in absence of a primary selection marker.....	137
4.4.2	Recombination of lox66 and lox5171 drastically reduces exchange efficiency .	139
4.4.3	Expression strength depends on various parameters and is not locus-specific	141
<b>5</b>	<b>Conclusion &amp; outlook .....</b>	<b>146</b>
<b>6</b>	<b>References.....</b>	<b>148</b>
	List of Abbreviations .....	i
	List of Tables.....	v
	List of Figures.....	vi
	Appendix .....	ix
A1	History of preexisting and generated cell lines .....	ix
A2	CRISPR/Cas9n target sites .....	x
A3	Used Oligos .....	x
A4	Plasmid maps .....	xiii
A5	Modified target sequences in GalNAc-K.O. clones.....	xxv
A6	Modified target sequences in GS-K.O. clones.....	xxviii
A7	Predicted Integration and recombination sites .....	xxix